Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines.
Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.
Kim
Dae-Sun
DS
The Catholic University of Korea, Department of Biotechnology, 43-1 yeokgok 2-dong, Wonmi-gu, Bucheon-si, Gyunggi-do 420-743, Republic of Korea.
Nam
Jae-Hwan
JH
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D003384:Coxsackievirus Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D004770:Enterovirus / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors; D006801:Humans; D009154:Mutation / Q000235:genetics; D011991:Receptors, Virus / Q000235:genetics; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D011991:Receptors, Virus; D014613:Vaccines, Attenuated; C105941:coxsackievirus B receptor